Molecules, Vol. 26, Pages 3208: Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme
Molecules, Vol. 26, Pages 3208: Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme
Molecules doi: 10.3390/molecules26113208
Authors:
Jaya Prabhakaran
Andrei Molotkov
Akiva Mintz
J. John Mann
Neuroinflammation and cyclooxygenase-2 (COX-2) upregulation are associated with the pathogenesis of degenerative brain diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), epilepsy, and a response to traumatic brain injury (TBI) or stroke. COX-2 is also induced in acute pain, depression, schizophrenia, various cancers, arthritis and in acute allograft rejection. Positron emission tomography (PET) imaging allows for the direct measurement of in vivo COX-2 upregulation and thereby enables disease staging, therapy evaluation and aid quantifying target occupancy of novel nonsteroidal anti-inflammatory drugs or NSAIDs. Thus far, no clinically useful radioligand is established for monitoring COX-2 induction in brain diseases due to the delay in identifying qualified COX-2-selective inhibitors entering the brain. This review examines radiolabeled COX-2 inhibitors reported in the past decade and identifies the most promising radioligands for development as clinically useful PET radioligands. Among the radioligands reported so far, the three tracers that show potential for clinical translation are, [11CTMI], [11C]MC1 and [18F]MTP. These radioligands demonstrated BBB permeablity and in vivo binding to constituti...
Source: Molecules - Category: Chemistry Authors: Jaya Prabhakaran Andrei Molotkov Akiva Mintz J. John Mann Tags: Review Source Type: research
More News: ALS | Arthritis | Bone Graft | Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemistry | Depression | Epilepsy | Neurology | Pain | PET Scan | Rheumatology | Schizophrenia | Stroke